Free Trial
NASDAQ:PMVP

PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis

PMV Pharmaceuticals logo
$1.02 +0.02 (+2.00%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$1.02 +0.00 (+0.29%)
As of 04/17/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PMV Pharmaceuticals Stock (NASDAQ:PMVP)

Key Stats

Today's Range
$0.95
$1.04
50-Day Range
$0.87
$1.44
52-Week Range
$0.82
$2.26
Volume
89,356 shs
Average Volume
258,316 shs
Market Capitalization
$52.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67
Consensus Rating
Buy

Company Overview

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

PMV Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

PMVP MarketRank™: 

PMV Pharmaceuticals scored higher than 47% of companies evaluated by MarketBeat, and ranked 748th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PMV Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    PMV Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about PMV Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.06) to ($1.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PMV Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PMV Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PMV Pharmaceuticals has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about PMV Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.91% of the float of PMV Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    PMV Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in PMV Pharmaceuticals has recently decreased by 5.51%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    PMV Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    PMV Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.91% of the float of PMV Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    PMV Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in PMV Pharmaceuticals has recently decreased by 5.51%, indicating that investor sentiment is improving significantly.
  • Search Interest

    1 people have searched for PMVP on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PMV Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.60% of the stock of PMV Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about PMV Pharmaceuticals' insider trading history.
Receive PMVP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PMVP Stock News Headlines

PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)
PMV Pharmaceuticals sees cash runway to end of 2026
The U.S. just rewrote the rules of retirement
For decades, Wall Street told retirees to stick with big names, stay diversified, and live off dividends. But Tim Plaehn says those rules no longer apply — and the 2025 trade war is exposing just how fragile that plan really was. Tim just released a video briefing explaining how the global shift is hammering traditional income stocks — and how a few U.S.-focused companies are built to weather the chaos.
PMV Pharmaceuticals files $200M mixed securities shelf
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
See More Headlines

PMVP Stock Analysis - Frequently Asked Questions

PMV Pharmaceuticals' stock was trading at $1.51 at the beginning of the year. Since then, PMVP stock has decreased by 32.5% and is now trading at $1.02.
View the best growth stocks for 2025 here
.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) posted its earnings results on Monday, March, 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.08.

PMV Pharmaceuticals (PMVP) raised $126 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO.

Top institutional shareholders of PMV Pharmaceuticals include Assenagon Asset Management S.A. (0.22%). Insiders that own company stock include Deepika Jalota, Michael Carulli and Orbimed Advisors Llc.
View institutional ownership trends
.

Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PMV Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), NIO (NIO), Meta Platforms (META), Plug Power (PLUG), Aptose Biosciences (APTO) and Clean Energy Fuels (CLNE).

Company Calendar

Last Earnings
3/03/2025
Today
4/18/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PMVP
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.67
High Stock Price Target
$6.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+455.6%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.41 per share
Price / Book
0.23

Miscellaneous

Free Float
47,814,000
Market Cap
$52.97 million
Optionable
Optionable
Beta
1.49
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:PMVP) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners